Updated:
23andMe
23andMe is a DTC genetic testing company with 11M+ customers, FDA-cleared health reports, and a research unit that has published 300+ studies.
23andMe
23andMe was co-founded in 2006 by Anne Wojcicki, Linda Avey, and Paul Cusenza as a direct-to-consumer genetic testing service. Wojcicki, then married to Google co-founder Sergey Brin, remained CEO until 2024; the firm went public via a SPAC merger with VG Acquisition Corp in 2021, valuing the combined entity at $3.5 billion (per SEC filing, 2021). The underlying wealth context has remained largely opaque: Wojcicki's personal fortune and Brin's early personal investment provided seed capital, but the firm has never structured itself as a family office. 23andMe generates revenue through genotyping kits and subscription services — 23andMe+ Premium ($69/year) and 23andMe+ Total Health ($199/year) — offering ancestry breakdowns into 4,500+ regions and health reports on 95+ conditions. The firm's research arm has published over 300 papers, including studies on Parkinson's disease, depression, and COVID-19 genetic susceptibility. It maintains FDA clearance for multiple health reports, a structural moat in the DTC genomics space. The database of 11+ million genotyped customers is the primary asset; the firm licenses aggregated, de-identified data to pharmaceutical partners. As of May 2025, the firm employs an undisclosed number of staff across offices in Sunnyvale (HQ), Santa Clara, New York, Mountain View, Seattle, and Austin. In September 2024, the board removed co-founder Anne Wojcicki as CEO, installing a new management team to explore strategic options, including a potential sale or privatization (per Bloomberg, September 2024). The 23andMe Research Institute continues to operate as an internal R&D entity, but no separate philanthropic foundation has been disclosed. 23andMe's structural differentiator is its vertical integration of consumer genotyping, clinical-grade data licensing, and subscription-based health insights — a model that no other DTC genomics competitor has replicated at scale. The firm's fate now hinges on whether its board can stabilize revenue growth and monetize the database without alienating its privacy-conscious customer base.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Sunnyvale
Corporate office
Sunnyvale, CA, United States
Additional offices
Santa Clara, CA · New York, NY · Mountain View, CA · Seattle, WA · Austin, TX
Sector focus
Frequently asked questions
Who runs investment decisions at 23andMe?
23andMe does not operate as an investment firm. The company's strategic direction is set by its board of directors, which as of 2025 has not publicly named a permanent CEO after Anne Wojcicki's removal in September 2024. Investment-related decisions, such as data licensing deals or capital allocation, are handled by the executive team under board oversight.
How does 23andMe generate revenue beyond kit sales?
In addition to one-time kit purchases, 23andMe offers two subscription tiers — 23andMe+ Premium for ancestry and health reports ($69/year) and 23andMe+ Total Health ($199/year) that includes exome sequencing and blood testing. The firm also licenses aggregated, de-identified genetic data to pharmaceutical and research partners, which has been a key revenue stream for its drug discovery arm.
Is 23andMe structured as a family office or a venture firm?
No. 23andMe is a publicly traded company (NASDAQ: ME) following its 2021 SPAC merger. It is not a family office, though its early capital included personal investment from Anne Wojcicki and Sergey Brin. The firm's corporate structure is that of a biotechnology/consumer genetics company with a research unit.
What investment stages does 23andMe target?
23andMe is not an asset manager and does not target investment stages. The firm's business model is operational — selling genetic testing kits, subscription services, and data licenses — rather than deploying capital into external companies or funds.
Does 23andMe participate in fund commitments or only direct deals?
23andMe does not participate in fund commitments or direct investment deals. The company's research collaborations with pharmaceutical firms (e.g., GSK) are structured as data-access partnerships, not equity investments.
How does 23andMe protect customer data?
23andMe states on its website that it uses enhanced measures to keep customer data secure and offers privacy-by-design controls. Customers can choose whether to participate in research; data shared for research is de-identified and aggregated. The firm has not disclosed a specific data-breach incident affecting customer consent choices since its 2023 security breach (per company disclosures, 2023).
What is the 23andMe Research Institute and how is it funded?
The 23andMe Research Institute is the firm's internal R&D division, funded by corporate revenue. It has published over 300 peer-reviewed studies, including research on Parkinson's disease, depression, and COVID-19. It does not operate as a separate philanthropic foundation; its budget is part of 23andMe's overall operational expenses.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: